Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer

• Prif Awduron: Helen Creedon (Awdur), Lucy A. Balderstone (Awdur), Morwenna Muir (Awdur), Jozef Balla (Awdur), Laura Gomez-Cuadrado (Awdur), Natasha Tracey (Awdur), Joseph Loane (Awdur), Teresa Klinowska (Awdur), William J. Muller (Awdur), Valerie G. Brunton (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: The Company of Biologists, 2016-02-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies presents a major clinical problem. Although preclinical studies have identified a number of possible mechanisms, clinical validation has been difficult. This is most likely to reflect the reliance on cell-line models th...